ciltacabtagene autoleucel
Drug Details
- Generic Name
- ciltacabtagene autoleucel
- Brand Names
- CARVYKTI
- Application Number
- BLA125746
- Sponsor
- Janssen Biotech, Inc.
- NDC Codes
- 1
- Dosage Forms
- INJECTION, SUSPENSION
- Routes
- INTRAVENOUS
- Active Ingredients
- CILTACABTAGENE AUTOLEUCEL
Indications and Usage
1 INDICATIONS AND USAGE CARVYKTI is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. CARVYKTI is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. ( 1 )